Oligonucleotide-Based Therapeutics Conference

Convening industry and health authorities to inform, educate, and share advancements in oligonucleotide-based therapeutic product development.

Early Bird Ends

DAYS

HOURS

MINUTES

SECONDS

返回 Agenda

Session 3 Tracks 1 and 2: Regulatory Considerations of Novel Conjugates: Translational and Clinical Pharmacology Perspectives

Independent Consultant

United States

Principal Scientist, Discovery Safety Specialist

AstraZeneca R&D, Sweden

Session 3 Tracks 1 and 2: Regulatory Considerations of Novel Conjugates: Translational and Clinical Pharmacology Perspectives